Literature DB >> 25940789

Exosome isolation: a microfluidic road-map.

A Liga1, A D B Vliegenthart, W Oosthuyzen, J W Dear, M Kersaudy-Kerhoas.   

Abstract

Exosomes, first isolated 30 years ago, are nanoscale vesicles shed by most types of cells. The nucleic acid rich content of these nanoparticles, floating in virtually all bodily fluids, has great potential for non-invasive molecular diagnostics and may represent a novel therapeutic delivery system. However, current isolation techniques such as ultracentrifugation are not convenient and do not result in high purity isolation. This represents an interesting challenge for microfluidic technologies, from a cost-effective perspective as well as for enhanced purity capabilities, and point-of-care acquisition and diagnosis. In this frontier review, we present the current challenges, comment the first microfluidic advances in this new field and propose a roadmap for future developments. This review enables biologists and clinicians familiar with exosome enrichment to assess the performance of novel microfluidic devices and, equally, enables microfluidic engineers to educate themselves about this new class of promising biomarker-rich particles and the challenges arising from their clinical use.

Entities:  

Mesh:

Year:  2015        PMID: 25940789     DOI: 10.1039/c5lc00240k

Source DB:  PubMed          Journal:  Lab Chip        ISSN: 1473-0189            Impact factor:   6.799


  101 in total

Review 1.  Using exosomes, naturally-equipped nanocarriers, for drug delivery.

Authors:  Elena V Batrakova; Myung Soo Kim
Journal:  J Control Release       Date:  2015-08-01       Impact factor: 9.776

Review 2.  Circulating Exosomes of Neuronal Origin as Potential Early Biomarkers for Development of Stroke.

Authors:  Ghada Yousif; Shahnaz Qadri; Mahmoud Haik; Yousef Haik; Aijaz Sultan Parray; Ashfaq Shuaib
Journal:  Mol Diagn Ther       Date:  2021-01-16       Impact factor: 4.074

Review 3.  Extracellular vesicles in liver disease and potential as biomarkers and therapeutic targets.

Authors:  Gyongyi Szabo; Fatemeh Momen-Heravi
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-06-21       Impact factor: 46.802

Review 4.  Emerging diagnostic, prognostic and therapeutic biomarkers for ovarian cancer.

Authors:  Khalid El Bairi; Abdul Hafeez Kandhro; Adel Gouri; Wafaa Mahfoud; Noureddine Louanjli; Brahim Saadani; Said Afqir; Mariam Amrani
Journal:  Cell Oncol (Dordr)       Date:  2016-12-15       Impact factor: 6.730

5.  Microfluidics in Malignant Glioma Research and Precision Medicine.

Authors:  Meghan Logun; Wujun Zhao; Leidong Mao; Lohitash Karumbaiah
Journal:  Adv Biosyst       Date:  2018-04-02

6.  Microfluidic approaches for cell-based molecular diagnosis.

Authors:  Dong Jun Lee; John Mai; Tony Jun Huang
Journal:  Biomicrofluidics       Date:  2018-09-14       Impact factor: 2.800

Review 7.  Extracellular vesicles as cancer liquid biopsies: from discovery, validation, to clinical application.

Authors:  Zhen Zhao; Jia Fan; Yen-Michael S Hsu; Christopher J Lyon; Bo Ning; Tony Y Hu
Journal:  Lab Chip       Date:  2019-03-27       Impact factor: 6.799

Review 8.  Extracellular vesicle isolation and characterization: toward clinical application.

Authors:  Rong Xu; David W Greening; Hong-Jian Zhu; Nobuhiro Takahashi; Richard J Simpson
Journal:  J Clin Invest       Date:  2016-04-01       Impact factor: 14.808

9.  Nanoscale lateral displacement arrays for the separation of exosomes and colloids down to 20 nm.

Authors:  Benjamin H Wunsch; Joshua T Smith; Stacey M Gifford; Chao Wang; Markus Brink; Robert L Bruce; Robert H Austin; Gustavo Stolovitzky; Yann Astier
Journal:  Nat Nanotechnol       Date:  2016-08-01       Impact factor: 39.213

10.  Aptamer-Conjugated Extracellular Nanovesicles for Targeted Drug Delivery.

Authors:  Yuan Wan; Lixue Wang; Chuandong Zhu; Qin Zheng; Guoxiang Wang; Jinlong Tong; Yuan Fang; Yiqiu Xia; Gong Cheng; Xia He; Si-Yang Zheng
Journal:  Cancer Res       Date:  2017-12-07       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.